TLDR
- HeartBeam (BEAT) stock jumped as much as 90% before settling up 62% to 71 cents.
- The FDA granted Breakthrough Device Designation for HeartBeam’s at-home heart attack assessment tool.
- The agency approved the request in under 30 days, beating its usual 60-day review window.
- The designation could speed up Medicare coverage for the device.
- HeartBeam pegs the heart attack market opportunity at roughly $15 billion.
HeartBeam (BEAT) stock climbed sharply this week after the company landed a major regulatory win. Shares were up 62% to 71 cents at the time of publication, having surged as much as 90% during the session.
The jump came after the U.S. Food and Drug Administration granted Breakthrough Device Designation for the HeartBeam System. The tool is designed to help assess potential heart attacks while patients are still at home.
The FDA moved fast on this one. It approved the request within 30 days, well ahead of its standard 60-day statutory review period.
What the Designation Means
Breakthrough Device status isn’t approval. It’s a fast-track label that gives HeartBeam priority access to FDA reviewers as it works through the clinical and regulatory process.
That includes closer collaboration on study design and a quicker path toward eventual clearance. It also matters for reimbursement.
The designation serves as a prerequisite for certain expedited Medicare coverage pathways. Federal health officials have floated a plan that could let qualifying devices get national coverage determinations the same day they clear regulatory review.
HeartBeam also applied for a separate federal program that tracks products through their entire life cycle. That’s another layer of support as the company moves toward a larger clinical trial.
The Technology and the Market
The HeartBeam System builds on the company’s existing 3D ECG platform. That’s the same tech behind its already FDA-cleared arrhythmia product.
Because of that overlap, the company doesn’t expect to need new hardware. It’s leaning on infrastructure it has already built and tested.
The 3D ECG approach captures the heart’s electrical activity from three different angles. That’s meant to let doctors spot signs of a heart attack the moment symptoms hit, no matter where the patient is.
Right now, the gold standard tool for that job, the 12-lead ECG, mostly lives in hospitals and clinics. HeartBeam wants to put that capability in people’s homes instead.
The company sees a $15 billion opportunity in the heart attack detection space alone. It frames that as part of a broader $40 billion-plus cardiac platform market.
More than 20 million adults in the U.S. carry elevated heart attack risk, according to the company. That’s a wide pool of potential users for a home-based tool.
Supporting data came from a few sources. That includes proof-of-concept results presented at the 2025 American Heart Association Scientific Sessions.
It also includes findings from the ALIGN-ACS pilot study, which enrolled 134 patients. Together, that data helped convince the FDA to move quickly.
Looking ahead, HeartBeam plans to work with the FDA on designing a larger, multicenter pivotal study. Patient enrollment is expected to start shortly after that design gets finalized.
The company also has a couple of near-term updates on the calendar. It’s expected to share more ALIGN-ACS data at the TCT conference in the coming weeks.
It also plans updates on its separate HEADSTART-ACS study. Both could give investors a clearer read on how the technology is progressing toward a full pivotal trial.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
